- Clinical Trials
- February 2024
- 80 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Report
- March 2024
- 161 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Report
- February 2024
- 130 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- January 2023
- 95 Pages
Global
From €2392EUR$2,490USD£2,045GBP
- Report
- December 2020
- 314 Pages
Global
From €6678EUR$6,950USD£5,709GBP
- Report
- August 2022
- 117 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,161GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,245GBP
- Drug Pipelines
- March 2021
Global
From €2402EUR$2,500USD£2,054GBP
- Drug Pipelines
- July 2020
- 667 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Report
- September 2023
- 106 Pages
Global
From €3500EUR$3,902USD£3,097GBP
Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition that affects the lungs and can lead to respiratory failure. Treatment for ARDS typically involves the use of respiratory drugs, such as bronchodilators, corticosteroids, and antibiotics. These drugs are used to reduce inflammation, improve oxygenation, and reduce the risk of infection. In addition, supportive care, such as mechanical ventilation, is often necessary to help patients with ARDS recover.
The ARDS drug market is highly competitive, with a number of companies offering a range of products. These include pharmaceutical companies, such as GlaxoSmithKline, Merck, and Pfizer, as well as biotechnology companies, such as Amgen and Biogen. Additionally, there are a number of generic drug manufacturers that offer lower-cost alternatives to branded drugs. Show Less Read more